Business
Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, N
About this update from Talon Capital Corp.
[{"type":"text","content":"SHANGHAI, April 9, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital.","length":597,"tagName":"p"},{"type":"text","content":"Proceeds will be strategically allocated to accelerate Oricell's global expansion and clinical development, while strengthening its technological capabilities and paving the way to capital market milestones.","length":216,"tagName":"p"},{"type":"text","content":"As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo (Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race.","length":501,"tagName":"p"},{"type":"text","content":"OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials. Clinical readouts have demonstrated a best-in-class efficacy and safety profile, with data highlighted at major forums including the ASCO Annual Meeting. With these promising results, Ori-C101 is positioned to become the first-in-class CAR-T therapy approved globally for HCC.","length":553,"tagName":"p"},{"type":"text","content":"Beyond its lead asset, Oricell is aggressively advancing a diverse portfolio of next-generation modalities, including secreted, rapid-production, and in vivo CAR-T programs.","length":173,"tagName":"p"},{"type":"text","content":"Dr. Huanfeng Yang, Chairman and CEO of Oricell The...